(NYSE: HLN) Haleon's forecast annual revenue growth rate of -3.32% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 37.1%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 22.74%.
Haleon's revenue in 2025 is $14,588,311,688.On average, 19 Wall Street analysts forecast HLN's revenue for 2026 to be $108,423,352,569,184, with the lowest HLN revenue forecast at $100,375,171,404,950, and the highest HLN revenue forecast at $114,445,862,853,481. On average, 19 Wall Street analysts forecast HLN's revenue for 2027 to be $113,301,313,387,687, with the lowest HLN revenue forecast at $105,425,723,015,914, and the highest HLN revenue forecast at $120,141,359,004,694.
In 2028, HLN is forecast to generate $120,513,791,767,373 in revenue, with the lowest revenue forecast at $112,756,289,832,547 and the highest revenue forecast at $124,465,212,542,138.